Меню
Набор скоро начнётся NCT05440123

Experimentation With Screening for Bronchopulmonary Cancer and Primary Cardiovascular Prevention, Early Management of COPD and an Offer Exempted From Smoking Cessation

Наблюдательное the Rate of Participation in Screening for PBC

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
В протоколе указаны: screening for bronchopulmonary cancer.
Кому может быть актуально
Состояния в реестре: the Rate of Participation in Screening for PBC. Базовые параметры: 55 лет — 74 лет · Все.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
Список центров уточняется — проверьте первичный протокол.
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Официальное название

Bronchopulmonary Cancer Screening Program and Primary Cardiovascular Prevention, Early Management of COPD and Smoking Cessation

Обзор

The study consists of recruiting a target population by sending a letter from the Regional Center for Cancer Screening in Ile de France. In the screening program, a battery of examinations will be carried out at inclusion, one year, 2 years, 3 years, 4 years and 5 years.

Подробное описание

The patients will be recruited by correspondence by by sending a letter from the Regional Center for Cancer Screening in Ile de France.

When the patient has agreed to participate, a screening program will be carried out The screening program includes performing a low-dose chest CT scan (STBD), spirometry, blood sampling (biobank + screening for cardiovascular risk factors) on inclusion, at 1 year and at 2 years. Subsequently, a telephone interview will be scheduled for 3 years to collect medical information, for a total follow-up period of 5 years. At each visit, a structured offer of smoking cessation will be proposed and a collection of the quality of life will be carried out. Each year, a telephone call from participants will be scheduled in order to maximize participation

Вмешательства

  • Другое screening for bronchopulmonary cancer
    The screening program includes performing a low-dose chest CT scan (STBD), spirometry, blood sampling (biobank + screening for cardiovascular risk factors) on inclusion, at 1 year and at 2 years. Subsequently, a telephone interview will be scheduled for 3 years to collect medical information, for a total follow-up period of 5 years. At each visit, a structured offer of smoking cessation will be proposed and a collection of the quality of life will be carried out. Each year, a telephone call from

Первичные конечные точки

  • Rate of population participation in PBC screening [Срок оценки: Baseline]

Критерии участия

Критерии включения

  • Women and men
  • Age: 55 to 74 years old
  • Smokers at more than 20 pack-years weaned for less than 15 years
  • Affiliated to a social security organization

Критерии исключения

  • Presence of signs of PBC
  • Subjects with a personal history of PBC of less than 5 years or under treatment
  • Presence of serious comorbidities involving the vital prognosis at 6 months
  • Subjects who have already benefited from a chest CT scan less than one year old.
  • Refusal to participate in the study
  • Absence of exposure to tobacco or insufficient exposure to tobacco or withdrawal > 15 years
  • Patient on long-term oxygen therapy
  • Metal implants (thorax, spine) which can cause a deterioration in the quality of the image of the low dose scanner
  • Subject included in another study protocol

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Дизайн исследования

Модель наблюдения
Когортное

Центры проведения

Список центров уточняется — проверьте первичный протокол.

Идентификаторы

NCT: NCT05440123 · LUMASCAN-2

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗